Avid Bioservices Inc (CDMO)

[biopharm]

new info to surface and with Vertex "new" PS Targeting compound and in combination with LOTS of prior info...I think Ampersand would be foolish if they are not out to maximize shareholder value and risk other info to come out showing they were part of the problem, not the solution

All should continue sending in the complaints to SEC FBI DOJ FDA and again, I ask nicely....for ALL to ask for the 100% file for the "Fairness Opinion .." given that Ampersand Capital should admit viewing while now they have to consider other options -- some things just may surprise everyone! and with CDMO receiving royalties on all IP asset based net sales..etc we are in for an eye opener

_________

Lavage lipidomics signatures in children with cystic fibrosis and protracted bacterial bronchitis.
Seidl E, et al. J Cyst Fibros. 2019.
Authors
Seidl E1, Kiermeier H1, Liebisch G2, Ballmann M3, Hesse S1, Paul-Buck K4, Ratjen F5, Rietschel E6, Griese M7.
Author information
1
Hauner Children's Hospital, Ludwig Maximilians University, German Center for Lung Research (DZL), Lindwurmstr. 4a, D-80337 Munich, Germany.
2
Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, Germany.
3
Department of Pediatric Pulmonology, University Rostock, Germany.
4
Praxis Prof. Karl Paul, Schöneberger Ufer 69, 10785 Berlin, Germany.
5
Hospital for Sick Children, University of Toronto, Canada.
6
CF-Centre, Faculty of Medicine, University of Cologne, Germany.
7
Hauner Children's Hospital, Ludwig Maximilians University, German Center for Lung Research (DZL), Lindwurmstr. 4a, D-80337 Munich, Germany. Electronic address: [e-mail].

Among the phospholipids, patients with CF had higher proportion of the non-surfactant membrane-lipids in the classes phosphatidylethanolamine based plasmalogens (PE P), phosphatidylethanolmine (PE) and phosphatidylserine (PS), but a lower proportion of phosphatidylcholine (PC) compared to healthy controls.
...
...

https://www.ncbi.nlm.nih.gov/m/pubmed/31029606/